INDICATIONS AND USAGE（适应症）

OZEMPIC is indicated:

as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction or non-fatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease.

DOSAGE（服用剂量）

Start OZEMPIC with a 0.25 mg subcutaneous injection once weekly for 4 weeks. The 0.25 mg dose is intended for treatment initiation and is not effective for glycemic control.

After 4 weeks on the 0.25 mg dose, increase the dosage to 0.5 mg once weekly.

If additional glycemic control is needed after at least 4 weeks on the 0.5 mg dose, the dosage may be increased to 1 mg once weekly. The maximum recommended dosage is 1 mg once weekly.

Administer OZEMPIC once weekly, on the same day each week, at any time of the day, with or without meals.

The day of weekly administration can be changed if necessary as long as the time between two doses is at least 2 days (>48 hours).

If a dose is missed, administer OZEMPIC as soon as possible within 5 days after the missed dose. If more than 5 days have passed, skip the missed dose and administer the next dose on the regularly scheduled day. In each case, patients can then resume their regular once weekly dosing schedule.

ADVERSE REACTIONS（不良反应）

Risk of Thyroid C-cell Tumors

Pancreatitis

Diabetic Retinopathy Complications

Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin

Acute Kidney Injury

Hypersensitivity

For full information, please refer to:

https://nctr-crs.fda.gov/fdalabel/services/spl/set-ids/b5399d16-01c1-4315-af3c-7619fee86621/spl-doc?hl=Ozempic

Ozempicinformation